Rheumatoid arthritis

Immunological Reviews

Volumn 204, Issue , 2005, Pages 55-73

  Goronzy, Jörg J ^a   Weyand, Cornelia M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CELL RECEPTOR; CHEMOKINE RECEPTOR; FRACTALKINE; FRACTALKINE RECEPTOR CX3CR1; HLA DR4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

AGING; B LYMPHOCYTE; CHRONIC INFLAMMATION; DISEASE COURSE; GERMINAL CENTER; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; LYMPH FOLLICLE; LYMPHOCYTE DEPLETION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SENESCENCE; SYNOVIUM; T LYMPHOCYTE ACTIVATION;

ARTHRITIS, RHEUMATOID; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; LYMPHOCYTES; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 16244399808     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00245.x     Document Type: Review

References (133)

1. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134: 695-706.
2. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003;9:1245-1250.
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-196.
4. Nishimoto N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-1769.
5. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:392-397.
6. Edwards JC, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.
7. Kremer JM, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915.
8. Weyand CM, Klimiuk PA, Goronzy JJ. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin Immunopathol 1998;20:5-22.
9. Weyand CM, Goronzy JJ. T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. Curr Opin Rheumatol 1999;11:210-217.
10. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 2004;6: S12-S18.
11. Weyand CM, Kang YM, Kurtin PJ, Goronzy JJ. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:259-266.
12. Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002;46:625-631.
13. Vossenaar ER, Van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004;6:107-111.
14. Suzuki A, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402.
15. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-541.
16. Berglin E, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-R308.
17. Nielen MM, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-386.
18. Blass S, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001;44:761-771.
19. Nishikawa S, Honda K, Vieira P, Yoshida H. Organogenesis of peripheral lymphoid organs. Immunol Rev 2003;195:72-80.
20. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003;3:292-303.
21. Weyand CM, Kurtin PJ, Goronzy JJ. Ectopic lymphoid Organogenesis: a fast track for autoimmunity. Am J Pathol 2001;159: 787-793.
22. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994;269:22027-22033.
23. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997;3:189-195.
24. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003;48:594-601.
25. Foxwell B, et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998;95:8211-8215.
26. Brennan F, Foey A. Cytokine regulation in RA synovial tissue: role of T cell/ macrophage contact-dependent interactions. Arthritis Res 2002;4:S177-S182.
27. Duke O, Panayi GS, Janossy G, Poulter LW. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. Clin Exp Immunol 1982;49:22-30.
28. Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997;151:1311-1319.
29. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93:221-225.
30. Berek C, Kim HJ. B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthritis. Semin Immunol 1997;9:261-268.
31. + T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol 1998;161:6390-6397.
32. Takemura S, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-1080.
33. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998;102:938-946.
34. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001;167:1935-1944.
35. Park Y, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM. Thrombospondin 2 Functions as an Endogenous Regulator of Angiogenesis and Inflammation in Rheumatoid Arthritis. Am J Pathol 2004;165:2087-2098.
36. Davis LS, et al. Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis. Am J Pathol 2002;160:357-367.
37. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999;90:65-78.
38. Kang YM, et al. CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med 2002;195:132S-1336.
39. Setoguchi K, et al. Suppression of T cell responses by chondromodulin I, a cartilage-derived angiogenesis inhibitory factor: therapeutic potential in rheumatoid arthritis. Arthritis Rheum 2004;50:828-839.
40. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-4718.
41. Goronzy JJ, Weyand CM. B cells as a therapeutic target in autoimmune disease. Arthritis Res Ther 2003;5:131-135.
42. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000;12:163-171; discussion 257-344.
43. McHeyzer-Williams LJ, Driver DJ, McHeyzer-Williams MG. Germinal center reaction. Curr Opin Hematol 2001;8:52-59.
44. Cyster JG. Leukocyte migration: scent of the T zone. Curr Biol 2000;10:R30-R33.
45. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999;17:399-433.
46. Tumanov AV, et al. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol Rev 2003;195:106-116.
47. Ruddle NH. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res 1999;19:119-125.
48. Drayton DL, Chan K, Lesslauer W, Lee J, Ying XY, Ruddle NH. Lymphocyte traffic in lymphoid organ neogenesis. differential roles of LTalpha and LTalphabeta. Adv Exp Med Biol 2002;512:43-48.
49. Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol 1998;161:6853-6860.
50. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003;15:15-21.
51. Loetscher P, Moser B. Homing chemokines in rheumatoid arthritis. Arthritis Res 2002;4:233-236.
52. Muller G, Lipp M. Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development. Curr Opin Immunol 2003;15:217-224.
53. Shi K, et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001;166:650-655.
54. + T cell migration within synovial tissue. Arthritis Rheum 2003;48:2472-2482.
55. Bofill M, Akbar AN, Amlot PL. Follicular dendritic cells share a membrane-bound protein with fibroblasts. J Pathol 2000;191:217-226.
56. Lindhout E, van Eijk M, van Pel M, Lindeman J, Dinant HJ, de Groot C. Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells. J Immunol 1999;162:5949-5956.
57. Cancro MP. Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004;197:89-101.
58. Seyler TM, et al. Biological functions of BLyS and APRIL in rheumatoid synovitis. Arthritis Rheum 2003;48:S457.
59. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-288.
60. Page G, Miossec P. Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol 2004;204:28-38.
61. Zheng B, Han S, Takahashi Y, Kelsoe G. Immunosenescence and germinal center reaction. Immunol Rev 1997;160:63-77.
62. Scotet E, et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med 1996;184:1791-1800.
63. Scotet E, et al. Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur J Immunol 1999;29:973-985.
64. Grubeck-Loebenstein B, Berger P, Saurwein-Teissl M, Zisterer K, Wick G. No immunity for the elderly. Nat Med 1998;4:870.
65. Albright JF, Albright JW. Aging, Immunity, and Infection. Totowa: Human Press, 2003.
66. Centers for Disease Control and Prevention (U.S.). Natl Vital Statistics Report 1998 Natl Vital Statistics Reports 1998;47:26-36.
67. Fry TJ, Mackall CL. Current concepts of thymic aging. Springer Semin Immunopathol 2002;24:7-22.
68. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000;18:529-560.
69. Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis. Arthritis Rheum 1995;38:1242-1251.
70. Szakal AK, Aydar Y, Balogh P, Tew JG. Molecular interactions of FDCs with B cells in aging. Semin Immunol 2002;14:267-274.
71. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat Rev Immunol 2002;2:699-706.
72. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:9203-9208.
73. Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther 2003;5:225-234.
74. Kong FK, Chen CL, Six A, Hockett RD, Cooper MD. T cell receptor gene deletion circles identify recent thymic emigrants in the peripheral T cell pool. Proc Natl Acad Sci USA 1999;96:1536-1540.
75. Douek DC, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
76. Ponchel F, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002;100:4550-4556.
77. Hazenberg MD. et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000;6:1036-1042.
78. Hazenberg MD, Borghans JA, de Boer RJ, Miedema F. Thymic output: a bad TREC record. Nat Immunol 2003;4:97-99.
79. Goronzy JJ, Weyand CM. Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis. Trends Immunol 2001;22:251-255.
80. Schonland SO, et al. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lyrnphoid cell lineages. Proc Natl Acad Sci USA 2003;100:13471-13476.
81. Weyand CM, Goronzy JJ. Stem cell aging and autoimmunity in rheumatoid arthritis. Trends Mol Med 2004;10:426-433.
82. Itoh K, et al. Clonal expansion is a characteristic feature of the B-cell repetoire of patients with rheumatoid arthritis. Arthritis Res 2000;2:50-58.
83. Johnson SA, Gambier JC. Ageing, autoimmunity and arthritis: Senescence of the B cell compartment - implications for humoral immunity. Arthritis Res Ther 2004;6:131-139.
84. Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002;100: 474-482.
85. Kochi Y, et al. Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences. Arthritis Rheum 2004;50:63-71.
86. + human T cells: activation requirements and association with HLA-DR alleles. J Immunol 1996;157:4771-4780.
87. Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human thymus function. Blood 2002;99:2851-2858.
88. Moulias R, et al. Age-related increase in autoantibodies. Lancet 1984;1:1128-1129.
89. + T cells in lymphopenic hosts. Immunity 1999;11:183-190.
90. Viret C, Wong FS, Janeway CA Jr. Designing and maintaining the mature TCR repertoire: the continuum of self-peptide: self-MHC complex recognition. Immunity 1999;10:559-568.
91. Schonland SO, et al. Homeostatic control of T-cell generation in neonates. Blood 2003;102:1428-1434.
92. Chamberlain WD, Falta MT, Kotzin BL. Functional subsets within clonally expanded CD8(+) memory T cells in elderly humans. Clin Immunol 2000;94:160-172.
93. + T cell clones in elderly humans. J Immunol 1997;158:4493-4499.
94. Naylor K, et al. The Influence of Age on T Cell Generation and T Cell Receptor Diversity (Submitted)
95. + T cell expansions in normal individuals and patients with rheumatoid arthritis. J Immunol 1995;154:3538-3547.
96. + T cell population of rheumatoid arthritis patients. J Immunol 1996;156:852-858.
97. + T cells in rheumatoid arthritis. Mol Med 1996;2:608-618.
98. Waase I, Kayser C, Carlson PJ, Goronzy JJ, Weyand CM. Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum 1996;39:904-913.
99. + T cells in severe rheumatoid arthritis. Arthritis Rheum 1997;40:1106-1114.
100. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998;95:14447-14452.
101. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003;197:451-460.
102. Gleeson PA, Toh BH, van Driel IR. Organ-specific autoimmunity induced by lymphopenia. Immunol Rev 1996;149: 97-125.
103. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:527-531.
104. Effros RB. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 1997;21:471-478.
105. Vallejo AN, Bryl E, Klarskov K, Naylor S, Weyand CM, Goronzy JJ. Molecular basis for the loss of CD28 expression in senescent T cells. J Biol Chem 2002;277:46940-46949.
106. + counterparts. J Immunol 1996;156:3587-3590.
107. + T cells: reversal by interleukin-12 stimulation. Blood 2003;101:3543-3549.
108. + T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum 2001;44:13-20.
109. Appay V, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002;168: 5954-5958.
110. Griffiths GM, Alpert S, Lambert E, McGuire J, Weissman IL. Perform and granzyme A expression identifying cytolytic lymphocytes in rheumatoid arthritis. Proc Natl Acad Sci USA 1992;89:549-553.
111. Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J Immunol 1998;161:1018-1025.
112. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4+CD28 null T cells are associated with defects in apoptotic pathways. J Immunol 2000;165:6301-6307.
113. Zhang X NT, Goronzy JJ, Weyand CM. Breakdown in the compartmentalization of central and effector memory CD4 T cells in rheumatoid arthritis (submitted).
114. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:212-217.
115. Yen JH, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001;193:1159-1167.
116. Nakajima T, et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res 2003;93:106-113.
117. +CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000;165:1138-1145.
118. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. Human NK-cell receptors. Immunol Today 2000;21:420-422.
119. Snyder MR, et al. Formation of the killer Ig-like receptor repertoire on CD4+CD28null T cells. J Immunol 2002;168:3839-3846.
120. Snyder MR, Weyand CM, Goronzy JJ. The double life of NK receptors: stimulation or co-stimulation? Trends Immunol 2004;25:25-32.
121. Snyder MR, Lucas M, Vivier E, Weyand CM, Goronzy JJ. Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD44+ T cells. J Exp Med 2003;197:437-449.
122. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol 2004;173: 3725-3731.
123. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001;19:291-330.
124. Martin MP, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002;169:2818-2822.
125. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003;100:9452-9457.
126. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790.
127. Ruth JH, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-1581.
128. Nanki T, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878-2883.
129. Sawai H, Park YW, Roberson J, Goronzy JJ, Weyand CM. Dominance of Stimulatory Signals in the Rheumatoid Synovial Microenvironment - A Role for Fractalkine-CX3CR1 Interactions (In press).
130. Goronzy JJ, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43-54.
131. Liuzzo G, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999;100:2135-2139.
132. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-2126.
133. Rittner HL, Zettl A, Jendro MC, Bartz-Bazzanella P, Goronzy JJ, Weyand CM. Multiple mechanisms support oligoclonal T cell expansion in rheumatoid synovitis. Mol Med 1997;3:452-465.